2021 update on thyroid-associated ophthalmopathy.
Neag EJ, Smith TJ.
J Endocrinol Invest. 2022 Feb;45(2):235-259. doi: 10.1007/s40618-021-01663-9. Epub 2021 Aug 20.
Cytokines in Thyroid-Associated Ophthalmopathy.
Zhang P, Zhu H.
J Immunol Res. 2022 Nov 14;2022:2528046. doi: 10.1155/2022/2528046. eCollection 2022.
Thyroid-associated ophthalmopathy: the role of oxidative stress.
Ma C, Li H, Lu S, Li X.
Front Endocrinol (Lausanne). 2024 Jul 11;15:1400869. doi: 10.3389/fendo.2024.1400869. eCollection 2024.
Thyroid-associated ophthalmopathy and ferroptosis: a review of pathological mechanisms and therapeutic strategies.
Ma C, Li H, Lu S, Li X.
Front Immunol. 2024 Dec 6;15:1475923. doi: 10.3389/fimmu.2024.1475923. eCollection 2024.
Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy.
Smith TJ.
Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101383. doi: 10.1016/j.beem.2020.101383. Epub 2020 Jan 31.
Single-cell BCR and transcriptome analysis reveals peripheral immune signatures in patients with thyroid-associated ophthalmopathy.
Li Q, An N, Liu C, Ding Y, Yang C, Ma X, Yang W, Piao J, Zhu J, Liu J.
Aging (Albany NY). 2024 May 9;16(9):8217-8245. doi: 10.18632/aging.205814. Epub 2024 May 9.
Advances in artificial intelligence in thyroid-associated ophthalmopathy.
Yi C, Niu G, Zhang Y, Rao J, Liu G, Yang W, Fei X.
Front Endocrinol (Lausanne). 2024 Apr 23;15:1356055. doi: 10.3389/fendo.2024.1356055. eCollection 2024.
Treating Thyroid Associated Ophthalmopathy in Pediatric Patients.
Dong T, Fu Z, Wang X.
Front Endocrinol (Lausanne). 2022 Jun 28;13:900204. doi: 10.3389/fendo.2022.900204. eCollection 2022.
IGF1 receptor and thyroid-associated ophthalmopathy.
Mohyi M, Smith TJ.
J Mol Endocrinol. 2018 Jul;61(1):T29-T43. doi: 10.1530/JME-17-0276. Epub 2017 Dec 22.
Graves' ophthalmopathy.
Bahn RS.
N Engl J Med. 2010 Feb 25;362(8):726-38. doi: 10.1056/NEJMra0905750.
